Omadacycline for Acute Bacterial Skin and Skin-Structure Infections

2019148 citationsJournal Article

Authors

William O’Riordan

Sinikka Green · Health Choice Network

J. Scott Overcash

Ivan Puljiz · University Hospital for Infectious Diseases "Dr Fran Mihaljevic"

Symeon Metallidis · AHEPA University Hospital

Jānis Gardovskis · Pauls Stradiņš Clinical University Hospital

Lynne Garrity-Ryan · Paratek Pharmaceuticals (United States)

Anita Das

Abstract

Omadacycline was noninferior to linezolid for the treatment of acute bacterial skin and skin-structure infections and had a similar safety profile. (Funded by Paratek Pharmaceuticals; OASIS-1 ClinicalTrials.gov number, NCT02378480 .).

Topics & Keywords

Antimicrobial Resistance in Staphylococcus Streptococcal Infections and Treatments Bacterial Identification and Susceptibility Testing

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 380, Issue 6, pp. 528-538

DOI: 10.1056/nejmoa1800170

Field-Weighted Citation Impact: 14.44